A less invasive treatment approach for bowel cancer could save over £1 billion
6 July 2022
New research from HDR UK suggests providing a break in treatment to patients with advanced bowel cancer could not only benefit a patient’s quality of life but could also help save £1.2 billion for the National Health Service in England.
New research suggests providing a break in treatment to patients with advanced bowel cancer could not only benefit a patient’s quality of life but could also help save £1.2 billion for the National Health Service (NHS) in England.
There are nearly 43,000 new bowel cancer cases in the UK every year, making it the fourth most common cancer in the UK and the second leading cause of cancer deaths, with more than 16,500 patients per year dying of the disease.
When bowel cancer can’t be completely removed by surgery, patients may be offered chemotherapy to shrink the tumour. Cetuximab may also be offered alongside the less toxic chemotherapy. Cetuximab works by targeting tumours with a defect in a particular pathway in the tumour cell.
When patients have a break from chemotherapy, they will continue to receive cetuximab alone. Despite a previous clinical trial that showed intermittent cetuximab to be a safe alternative to continuous cetuximab, treatment breaks beyond six weeks were prohibited in England. In other words, patients were required to continue to take cetuximab when on a break from chemotherapy, despite evidence that a break in cetuximab does not have any negative impact on patient outcome but can potentially benefit the patient’s quality of life.
This new research, led by researchers from HDR UK Northern Ireland and Queen’s University Belfast, in collaboration with Bowel Cancer UK, and a series of investigators across the UK, involved a historical analysis of both intermittent and continuous cetuximab approaches to determine their impact on both quality-of-life and treatment costs. The research has been published in the Journal of Cancer Policy, the key policy journal for cancer.
Using a health economic modelling and analysis approach, the researchers found that employing a treatment break approach with cetuximab would not have any negative impact on a patient’s quality-of-life and outcome, but could potentially save up to £1.2 billion for the health service. This work formed part of the crucial evidence that Bowel Cancer UK presented to NHS England to justify a change in bowel cancer treatment policy. This led to a temporary policy change by NHS England, removing the treatment break restrictions during the COVID-19 pandemic.
Dr Lisa Wilde, Director of Research and External Affairs at Bowel Cancer UK, comments: “Bowel cancer is the fourth most common cancer in the UK. We’ve been campaigning for several years to remove the treatment breaks policy in England, so we warmly welcome this scientifically-validated new evidence. It is clear that allowing people with advanced bowel cancer to take a break from their treatment benefits patients and saves the NHS money.
“At the beginning of the COVID-19 pandemic, NICE produced interim treatment guidance to maximise the safety of patients with cancer and make the best use of NHS resources, including allowing some patients to take breaks from their treatment. We’ve been working with NHS England to develop new guidance and hope to see this evidence reflected within the new recommendations.”
Professor Mark Lawler, Associate Director of Health Data Research Wales-Northern Ireland, Professor of Digital Health at Queen’s University Belfast, and senior author on the study, said: “This study is the first of its kind to use a cost minimization approach to look at the real costs of cancer therapies in the clinical trial setting. It highlights how substantial cost savings can potentially be achieved by reducing treatment, while also reinforcing the importance of therapy breaks to potentially increase tumour responsiveness to treatment once the therapy is reintroduced.
“Our study highlights how precise health economic evidence can influence health policy, championing reduced treatment intensity approaches without compromising patient outcomes, which is of particular relevance when addressing the reduced capacity and severe treatment backlogs experienced during the COVID pandemic.”
Dr Raymond Henderson, Senior Health Technology Assessment Manager at Salutem Insights Ltd and lead author on the paper, said: “Allowing patients to avail of treatment breaks not only can provide good value but also can enhance their quality of life and outcome.”
The study involved researchers from Queen’s University Belfast, Cardiff University, Imperial College London, University Hospital Leeds, University of Oxford, King’s College London, Bowel Cancer UK, Salutem Insights Ltd and Mount Vernon Centre for Cancer Treatment. Funding was through a Medical Research Council – Cancer Research UK Stratified Medicine Grant, a Health Data Research UK (HDR UK) grant, a grant from Cancer Focus Northern Ireland and through the Queen’s University Belfast Foundation.
Amendment: In an earlier version of the article, we said that the NHS has lifted the ban on treatment breaks for patients with advanced bowel cancer who are receiving cetuximab.
Bowel Cancer UK have advised that the NHS England policy is under review and a permanent lift of the ban has yet to be implemented. At present the treatment break rule remains suspended, meaning patients are able to take breaks longer than six weeks.
Updated 1 December 2022
Black internship paved the way for pre-term birth PhD research
16 March 2023
Fewa Laleye is a PhD student carrying out research to help predict which mothers are most at risk of pre-term births - helping ensure they receive the best care. An alumnus of the HDR UK Black...
CV workshop success sets the stage for further Alumni Network events
16 March 2023
A well-presented CV is the vital first step towards securing a new job, and is all the more important for those taking the first steps in the careers - our Alumni Network organised a successful...
How well is information on data access processes shared with the public? Introducing standards to inform good practice.
10 March 2023
Alan Holcroft is a member of the Public Advisory Board, interested in how organisations build the public’s trust and confidence in providing access and consent for their data to be used in...